Global Viral
Vector and Plasmid DNA Manufacturing Market is expected to reach $1,090.3
million by 2023 from $321.3 million in
2017, registering a CAGR of 22.6% during the forecast period.
Increase in funding for
R&D activities related to gene therapy due to prevalence of cancer and
other genetic disorders coupled with rise in awareness regarding gene therapy
drives the growth of the global viral vector and plasmid DNA manufacturing
market. However, high cost of gene therapies and risk of mutagenesis and other
impediments associated with gene therapy hamper the market growth. On the
contrary, surge in demand for synthetic genes and untapped potential across
emerging markets are expected to create lucrative opportunities for the market
players in future.
The key market players
analyzed in the report include Kaneka Eurogentec S.A., Brammer Bio, FUJIFILM Diosynth Biotechnologies, Spark
Therapeutics, UniQure NV, MassBiologics, Kaneka Eurogentec S.A., Brammer Bio, Catapult, Biotechnologies, Sanofi, and
Cobra Biologics.
The viral vector segment
dominated the market in 2017, contributing more than two-fifths of the total
market revenue, owing to advantages such as deep penetration in cells,
site-specific integration, and ability to differentiate between non-dividing
& dividing cells. Moreover, recent advancements in viral vectors to improve
efficacy by using gene delivery have supplemented the market growth. However,
the plasmid DNA segment is expected to register the fastest CAGR of 25.4%
during the forecast period, owing to the increased demand for personalized
medicines & target therapy and high success rate of prime boost
immunization strategies in plasmid DNA vaccines. Furthermore, the non-viral
vector is expected to witness steady growth during the forecast period.
The inherited disorder
segment is expected to grow at the fastest CAGR of 25.1% during the study
period, owing to the widespread applications of gene therapy and increase in
usage of personalized medicine to treat chronic diseases. On the other hand,
the cancer segment held the largest share in 2017, contributing nearly
two-thirds of the total revenue, owing to the growing demand for high quality
drugs and availability of versatile therapies for cancer treatment. The report
also analyzes the viral infection and others segments.
North
America accounted for more than two-fifths of the total market
revenue in 2017, owing to the high prevalence of cancer, increase in adoption
of experimental medicines, and rapid development of healthcare infrastructure.
However, the Asia-Pacific region
is expected to register the fastest CAGR of 29.5% through 2023, owing to rapid
industrialization, increase in disposable income, and proactive government
initiatives to improve healthcare infrastructure in the region. The other
regions analyzed in the report include Europe and Latin America, Middle East and Africa (LAMEA).
No comments:
Post a Comment